Brinkmann C, Abdel‐Wahab M, Bedogni F, et al. - Among patients receiving valve‐in‐valve transcatheter aortic valve replacement (VIV‐TAVR), this inquiry was conducted to ascertain outcome as well as its predictors of bioprosthetic valve fracture (BVF). From 14 international centers, a total of 81 cases of BVF‐VIV‐TAVR were selected. VARC‐2 defined device success was estimated to be 93%, most failures were because of residual high gradients. At 276 ± 237.6 days, event‐free survival was noted to be 95.4%. Findings demonstrated the safety of BVF as well as its ability to confer significant reduction in gradients, which continued to be stable at follow‐up. The following were revealed as predictors for higher final gradients: balloon‐expandable valves, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm.